hypertriglyceridemia in unani medicine

Efficacy of Habb -e- Shabyar in Hypertriglyceridemia associated with Metabolic Syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017498

Enrollment

Registered

2019-02-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Habb -e- Shabyar: 1.2 gm in the form of Habb at bed time orally for 60 days Control Intervention1: Placebo: 1.2 gm in the form of Habb at bed time orally for 60 days

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age between 35-60 years 2.Patients of both the genders 3.Central Obesity: Waist Circumference > 90 cm in Male, >80 cm in Female 4.Hypertriglyceridemia: Triglycerides 6.Fasting Blood Glucose: 126 - 7.Postprandial Blood Glucose Level: >140 - 8.Patient not taking treatment for Hypertriglyceridemia (Statins)

Exclusion criteria

Exclusion criteria: 1.K/c/o Systemic diseases 2.Pregnant and Lactating women 3.Type-1 Diabetes 4.Patients on weight loss medication 5.Fasting Plasma Glucose >=200mg/dl 6.BP >=139/89 mmHg 7.Patients on treatment for Hypertriglyceridemia (Statins)

Design outcomes

Primary

Measure	Time frame
Effect on triglycerides level (Normal / Decrease in TGL level)Timepoint: 0th day, 15th day, 30th day, 45th day, 60th day.	—

Secondary

Measure	Time frame
i)Effect on hyperglycemia (Decrease in glucose / HbA1c level) ii)Effect on HDLTimepoint: 0th day, 15th day, 30th day, 45th day, 60th day.	—

Countries

India

Contacts

Public ContactDr Mohd Aleemuddin Quamri

National Institute of Unani Medicine

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026